

Impact of the Practices of the Pharmaceutical Industry on Health: Selected References

Corporations and Health Watch is conducting a search for articles that assess the impact of corporate practices on health for various industries. This list includes selected publications from the peer-reviewed literature that describe and analyze the marketing, product design, retail and pricing practices of the pharmaceutical industry. We invite readers to submit additional references from the peer-reviewed or “grey” literature by sending them to response@corporationsandhealth.org.

1. Avorn J. Evaluating drug effects in the post-vioxx world: there must be a better way. *Circulation*. 2006;113(18):2173-6.
2. Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. *J Fam Pract*. 2000;49(12):1092-8.
3. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. *J Health Commun*. 2004;9:491-7.
4. Byrd-Bredbenner C, Grasso D. Prime-time health: an analysis of health content in television commercials broadcast during programs viewed heavily by children. *Int J Health Educ*. 1999;2(4):159-69.
5. Caprino L, Russo P. Developing a paradigm of drug innovation: an evaluation algorithm. *Drug Discov Today*. 2006;11(21-22):999-1006.
6. Chananie RA. Psychopharmaceutical advertising strategies: empowerment in a pill? *Sociol Spectr*. 2005;25(5):487-518.
7. Chow K, Tong HH, Lum S, Chow AH. Engineering of pharmaceutical materials: an industrial perspective. *J Pharm Sci*. 2007 [Epub ahead of print].
8. Cohen JC, Mrazek M, Hawkins L. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction. *Clin Pharmacol Ther*. 2007;81(3):445-9.
9. Conrad P, Leiter V. (2004). Medicalization, markets and consumers. *J Health Soc Behav*. 2004;45 Suppl:158-76.
10. Cooksey JA, Knapp KK, Walton SM, Cultice JM. Challenges to the pharmacist profession from escalating pharmaceutical demand. *Health Aff (Millwood)*. 2002;21(5):182-8.

11. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. *N Engl J Med.* 2007;357(7):673-81.
12. Federsel HJ. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. *Drug Discov Today.* 2006;11(21-22):966-74.
13. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. *Ann Fam Med.* 2007;5(1):6-13.
14. Garattini S, Bertele' V. How can we regulate medicines better? *BMJ.* 2007;335(7624):803-5.
15. Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries. *Health Policy.* 2008;85(3):305-13.
16. Gellad ZF, Lyles KW. Direct-to-consumer advertising of pharmaceuticals. *Am J Med.* 2007;120(6):475-80.
17. Gitlin M, Wilson L. Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing options to physician and retail dispensing. *Am J Ind Med.* 2007;50(4):303-15.
18. Jobe AH. Drug pricing in pediatrics: the egregious example of indomethacin. *Pediatrics.* 2007;119(6):1197-8.
19. Kaphingst KA, DeJong W, Rudd RE, Daltroy LH. A content analysis of direct-to-consumer television prescription drug advertisements. *J Health Commun.* 2004;9(6):515-28.
20. Khanna AK. Pharmaceutical industry's corporate social responsibility towards HIV/AIDS. *J Postgrad Med.* 2006;52(3):194-6.
21. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, Hinton L, Franks P. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. *JAMA* 2005;293(16):1995-2002.
22. Kempner J. Gendering the Migraine Market: Do Representations of Illness Matter? *Soc Sci Med.* 2006 Oct;63(8):1986-97.
23. Leibowitz AA, Sood N. Market power and state costs of HIV/AIDS drugs.

24. Int J Health Care Finance Econ. 2007;7(1):59-71.
25. Macias W, Lewis LS. A content analysis of direct-to-consumer (DTC) prescription drug web sites. J Advertising. 2003;32(4):43-56.
26. Mathis LL, Iyasu S. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned. Clin Pharmacol Ther. 2007;82(2):133-4.
27. McFadden DW, Calvario E, Graves C. The devil is in the details: the pharmaceutical industry's use of gifts to physicians as marketing strategy. J Surg Res. 2007;140(1):1-5.
28. Mehta A, Purvis CS. Consumer response to print prescription drug advertising. J Advertising Research 2003;43(2):194.
29. Miller HI, Henderson DR. Governmental influences on drug development: striking a better balance. Nat Rev Drug Discov. 2007;6(7):532-9.
30. Miller P. Role of pharmacoeconomic analysis in R&D decision making: when, where, how? Pharmacoeconomics. 2005;23(1):1-12.
31. Moncrieff J. Co-opting psychiatry: the alliance between academic psychiatry and the pharmaceutical industry. Epidemiol Psychiatr Soc. 2007;16(3):192-6.
32. Montoya ID, Jano E. Online pharmacies: safety and regulatory considerations. Int J Health Serv. 2007;37(2):279-89.
33. Openshaw MS. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada. Nurs Econ. 2005;23(6):307-11, 279.
34. Semin S, Aras S, Guldal D. Direct-to-consumer advertising of pharmaceuticals: developed countries experiences and Turkey. Health Expect. 2006;10:4-15.
35. Parker RS, Pettijohn CE. Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians. Health Mark Q. 2005;22(4):27-43.
36. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of Prescription Drugs to Consumers. N Engl J Med. 2002 Feb 14;346(7):498-505.
37. Sumpradit N, Ascione FJ, Bagozzi RP. A cross-media content analysis of motivational themes in direct-to-consumer prescription drug advertising. Clin Ther. 2004;26(1):135-54.

38. Topol EJ. Failing the public health--rofecoxib, Merck, and the FDA. *N Engl J Med*. 2004;351(17):1707-1709.
39. Villanueva P, Peiró S, Librero J, Pereiró I. Accuracy of pharmaceutical advertisements in medical journals. *Lancet*. 2003;361(9351):27-32.
40. Wall LL, Brown D. The high cost of free lunch. *Obstet Gynecol*. 2007;110(1):169-73.
41. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA*. 2000;283(3):373-380.
42. Weissman JS, Blumenthal D, Silk AJ, Newman M, Zapert K, Leitman R, Feibelmann S. Physicians report on patient encounters involving direct-to-consumer advertising. *Health Aff (Millwood)*. 2004;Suppl Web Exclusives:W4-219-33.
43. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. *Health Aff (Millwood)*. 2003;Suppl Web Exclusives:W3-82-95.
44. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. *Control Clin Trials*. 2004;25(6):535-52.
45. Williams-Jones,B. "Be ready against cancer, now": direct-to-consumer advertising for genetic testing. *New Genet Soc*. 2006;25(1):89-107.